COPD pathology in the small airways

Panminerva Medica

Volumn 53, Issue 1, 2011, Pages 51-70

  Caramori, G ^a   Casolari, P ^a   Giuffre S ^a   Barczyk, A ^b   Adcock, I ^c   Papi, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Medical University   (Poland)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Pathology; Smoke

Indexed keywords

BRONCHUS; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; PATHOLOGY; REVIEW; TRACHEA;

BRONCHI; CASE-CONTROL STUDIES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRACHEA;

EID: 79957437729     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (175)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; NIH Publication No 2701:1-100. Last update 2009. [Internet]. Available from http://www.goldcopd.com [cited 2010, Jun 7).
2. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977;115:195-205. (Pubitemid 8036155)
3. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006;367:1216-9. (Pubitemid 44316602)
4. Bruce N, Perez-Padilla R, Albalak R. Indoor air pollution in developing countries: a major environmental and public health challenge. Bull World Health Organ 2000;78:1078-92.
5. Birring SS, Brightling CE, Bradding P, Entwisle JJ, Vara DD, Grigg J et al. Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med 2002;166:1078-83. (Pubitemid 35178705)
6. Rivera RM, Cosio MG, Ghezzo H, Salazar M, Pérez-Padilla R. Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis 2008; 12:972-7.
7. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451 -64.
8. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004a;364:709-21. (Pubitemid 39140629)
9. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968;278:1355-60.
10. Van Brabandt H, Cauberghs M, Verbeken E, Moerman P, Lauweryns JM, Van de Woestijne KP. Partitioning of pulmonary impedance in excised human and canine lungs. J Appl Physiol 1983;55:1733-42. (Pubitemid 14210779)
11. Barnes PJ. Small airways in COPD. N Engl J Med 2004a;350:2635-7. (Pubitemid 38787995)
12. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004b;350:2645-53. (Pubitemid 38787999)
13. Hogg JC. State of the Art. Bronchiolitis in chronic obstructive pulmonary disease. PATS 2006;3:489-93. (Pubitemid 44285530)
14. Ohrui T, Yanai M, Sekizawa K, Morikawa M, Sasaki H, Takishima T. Effective site of bronchodilation by beta-adrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am Rev Respir Dis 1992; 146: 88-91.
15. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992;72:1016-23.
16. Corsico A, Milanese M, Baraldo S, Casoni GL, Papi A, Riccio AM et al. Small airway morphology and lung function in the transition from normality to chronic airway obstruction. J Appl Physiol 2003;95:441-7; discussion 435,
17. Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:1309-15. (Pubitemid 43900704)
18. Scherrer M. Asthma, chronic bronchitis, and pulmonary emphysema. Ciba Symp 1961;9:227-37.
19. Arias-Diaz J, Vara E, Torres-Melero J, García C, Baki W, RamírezArmengol JA et al. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 1994;74:1546-51. (Pubitemid 24302973)
20. Staal-van den Brekel AJ, Dentener MA, Drent M, Ten Velde GPM, Buurman WA, Wouters EFM. The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment. Respiratory Medicine 1998;92:76-83. (Pubitemid 28112046)
21. Marc MM, Korosec P, Kern I, Sok M, Ihan A, Kosnik M. Lung tissue and tumour-infiltrating T lymphocytes in patients with nonsmall cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD. Scand J Immunol 2007;66:694-702. (Pubitemid 350132632)
22. Baecher-Allan C, Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol 2006;16:98-105. (Pubitemid 43172058)
23. Gallimore A, Godkin A. Regulatory T cells and tumour immunity observations in mice and men. Immunology 2008;123:157-63.
24. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr et al. Tumor infiltrating foxp3+ regulatory T-cells are associated with recurrence in pathologic stage INSCLC patients. Cancer 2006;107:2866-72. (Pubitemid 44937041)
25. Domagala-Kulawik J, Maskey-Warzecowska M. T-regulatory cells in COPD or tumour environment. Eur Respir J 2009,34:284; author reply 285-6.
26. Weissler JC, Nicod LP, Toews GB. Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987;135:1353-7. (Pubitemid 18021534)
27. Pitchenik AE, Guffee J, Stein-Streilein J. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987;136:1327-32. (Pubitemid 18030259)
28. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007;178:2763-9. (Pubitemid 46333153)
29. Di Stefano A, Caramori G, Ricciardolo FLM, Capelli A, Adcock IM, Donner CF. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin Exp Allergy 2004;34:1156-67. (Pubitemid 39093053)
30. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small- cell lung cancer. Thorax 2004;59:679-81. (Pubitemid 39061531)
31. Watanabe S, Sato Y, Kodama T, Shimosato Y. Immunohistochemical study with monoclonal antibodies on immune response in human lung cancers. Cancer Res 1983;43:5883-9. (Pubitemid 14212657)
32. Caramori G, Bettoncelli G, Tosatto R, Arpinelli F, Visonà G, Invernizzi G et al. Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy. Monaldi Arch Chest Dis 2005;63:612.
33. Caramori G, Bettoncelli G, Carone M, Tosatto R, Di Blasi P, Pieretto A et al. Degree of control of physician-diagnosed asthma and COPD in Italy. Monaldi Arch Chest Dis 2007a;67:15-22. (Pubitemid 46840067)
34. Marian E, Baraldo S, Visentin A, Papi A, Saetta M, Fabbri LM, et al. Up-regulated membrane and nuclear leukotriene B4 receptors in COPD. Chest 2006;129:1523-30. (Pubitemid 43894981)
35. Bosken CH, Hards J, Gatter K, Hogg J. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using ¡mmunohistochemistry. Am Rev Respir Dis 1992;145:911-7.
36. Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J et al. Chronic obstructive pulmonary disease: role of bronchial mast cells and macrophages. Am J Pathol 1997;151:1785-90. (Pubitemid 27527941)
37. de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS et al. Transforming growth factor ßl and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1951 -7.
38. Lams BEA, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1518-23.
39. Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009;34:219-30.
40. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M et al. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 2006;173:751-8.
41. Deshmukh HS, McLachlan A, Atkinson JJ, Hardie WD, Korfhagen TR, Dietsch M et al. Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. Am J Respir Crit Care Med 2009;180:834-45.
42. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M et al. Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol 2000;278:L906-L913. (Pubitemid 30351045)
43. Tilley AE, Harvey BG, Heguy A, Hackett NR, Wang R, O'Connor TP et al. Down-regulation of the notch pathway in human airway epithelium in association with smoking and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:457-66.
44. Nagai A, West WW, Paul JL, Thurlbeck WM. The National Institutes of Health Intermittent Positive-pressure Breathing Trial: Pathology studies. I. Interrelationship between morphologic lesions. Am Rev Respir Dis 1985a; 132:937-45. (Pubitemid 16221377)
45. Nagai A, West WW, Thurlbeck WM. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Pathology studies, II: Correlation between morphologic findings, clinical findings and evidence of expiratory air-flow obstruction. Am Rev Respir Dis 1985b; 132:946-53. (Pubitemid 16221378)
46. Fabbri LM, Beghè B, Caramori G, Papi A, Saetta M. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 1998;53:803-8. (Pubitemid 28408724)
47. Snider GL. Chronic obstructive pulmonary disease: a continuing challenge. Am Rev Respir Dis 1986;133:942-4. (Pubitemid 16116530)
48. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
49. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al, on behalf of the Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Resp J 1995;8:1398-420.
50. The COPD guidelines group of the standards of care committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52 (suppl 5):Sl-28.
51. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS, on behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76. (Pubitemid 32378468)
52. Caramori G, Papi A. Smoking history effect on peripheral lung inflammation and gene transcription in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:2-3. (Pubitemid 43955236)
53. Furberg H, Sullivan PF, Maes H, Prescott CA, Lerman C, Bulik C, et al. The types of regular cigarette smokers: a latent class analysis. Nicotine Tob Res 2005;7:351-60. (Pubitemid 41418708)
54. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med 2004;140:426-33.
55. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9. (Pubitemid 32506590)
56. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.
57. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ et al; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
58. Wang IM, Stepaniants S, Boie Y, Mortimer JR, Kennedy B, Elliott M et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008;177:402-11. (Pubitemid 351317583)
59. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009;23:2810-9.
60. Szulakowski P, Crowther AJL, Jiménez LA, Donaldson K, Mayer R, Leonard TB et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:41-50. (Pubitemid 43955243)
61. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76. (Pubitemid 40638367)
62. Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Nat1 Acad Sei U S A 2004; 101:14895-900.
63. Ning W, Lee J, Kaminski N, Feghali-Bostwick CA, Watkins SC, Pilewski JM et al. Comprehensive analysis of gene expression on GOLD-2 Versus GOLD-O smokers reveals novel genes important in the pathogenesis of COPD. Proc Am Thorac Soc 2006;3:466. (Pubitemid 44285513)
64. Berger P, Laurent F, Begueret H, Perot V, Rouiller R, Raherison C et al. Structure and function of small airways in smokers: relationship between air trapping at CT and airway inflammation. Radiology 2003;228:85-94. (Pubitemid 36736073)
65. Fuke S, Betsuyacu T, Nasuhara Y, Morikawa T, Katoh H, Nishimura M. Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2004;31:405-12. (Pubitemid 39330950)
66. Betsuyaku T, Fuke S, Nasuhara Y, Morikawa T, Kondo S, Nishimura M. Diverse expression of antioxidants and inflammatory chemokines in terminal bronchiolar epithelium in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:471-2. (Pubitemid 44285515)
67. Nagai K, Betsuyaku T, Suzuki M, Nasuhara Y, Kaga K, Kondo S et al. Dual oxidase 1 and 2 expression in airway epithelium of smokers and patients with mild/moderate chronic obstructive pulmonary disease. Antioxid Redox Signal 2008;10:705-14. (Pubitemid 351225900)
68. Suzuki M, Betsuyaku T, Nagai K, Fuke S, Nasuhara Y, Kaga K et al. Decreased airway expression of vascular endothelial growm factor in cigarette smoke-induced emphysema in mice and COPD patients. Inhal Toxicol 2008a;20:349-59. (Pubitemid 351323659)
69. Gosselink JV, Hayashi S, Chau E, Cooper J, Elliott WM, Hogg JC. Evaluation of small sample cDNA amplification for microdissected airway expression profiling in COPD. COPD 2007;4:91-105. (Pubitemid 47164866)
70. Nishikawa M, Mak JC, Barnes PJ. Effect of short- and long-acting beta 2-adrenoceptor agonists on pulmonary beta 2-adrenoceptor expression in human lung. Eur J Pharmacol 1996;318; 123-9. (Pubitemid 27033214)
71. Casado B, Iadarola P, Luisetti M, Kussmann M. Proteomics-based diagnosis of chronic obstructive pulmonary disease: the hunt for new markers. Expert Rev Proteomics 2008;5:693-704.
72. Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllärniemi M et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res 2008;7:5125-32.
73. Lee EJ, In KH, Kim JH, Lee SY, Shin C, Shim JJ et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest 2009;135:344-52.
74. Ebert RV, Terrado MJ. The bronchiolar epithelium in cigarette smokers: observations with the scanning electron microscope. Am Rev Respir Dis 1975;111:4-11.
75. Vestbo J, Hogg JC. Convergence of the epidemiology and pathology of COPD. Thorax 2006;61:86-8. (Pubitemid 43106984)
76. de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32-9. (Pubitemid 46105306)
77. Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM et al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 2004;45:477-84. (Pubitemid 39524322)
78. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-78.
79. Aikawa T, Shimura S, Sasaki H, Takishima T, Yaegashi H, Takahashi T. Morphometric analysis of intraluminal mucus in airways in chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:477-82. (Pubitemid 19218367)
80. Hogg JC, Chu FSF, Tan WC, Sin DD, Patel SA, Pare PD et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-9. (Pubitemid 47358099)
81. Silvers GW, Maisel JC, Petty TL, Mitchell RS. Reduction in peripheral airway resistance in excised emphysematous lungs. Chest 1973;63(Suppl):32S-33S.
82. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and airflow limitation. Am J Respir Crit Care Med 2000; 161:1016-21. (Pubitemid 30171766)
83. Chung KF, Caramori G, Groneberg DA. Airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;351:1459-61; author reply 1459-61.
84. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003;163:1475-80. (Pubitemid 36758921)
85. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9. (Pubitemid 40216240)
86. Malhotra S, Lam S, Man SF, Gan WO, Sin DD. The relationship between stage 1 and 2 non-small cell lung cancer and lung function in men and women. BMC PuIm Med 2006;6:2.
87. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 19701977. N Engl J Med 1979;300:381-5.
88. Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 2007;175:547-53. (Pubitemid 46438936)
89. Giangreco A, Arwert EN, Rosewell IR, Snyder J, Watt FM, Stripp BR. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sei U S A 2009;106:9286-91.
90. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-35. (Pubitemid 40806415)
91. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al. Highly tumorigenic lung cancer CD 133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sei USA 2009;106:16281-6.
92. Caramori G, Papi A. Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer. Expert Rev Respir Med 2007b; 1:171-5.
93. Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis 1980;122:265-71. (Pubitemid 10087496)
94. Bosken CH, Wiggs BR, Pare PD, Hogg JC. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 1990;142:563-70. (Pubitemid 20292716)
95. Kuwano K, Bosken CH, Pare PD, Bai TR, Wiggs BR, Hogg JC. Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148:1220-5. (Pubitemid 23326017)
96. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE et al. CD8+ T- lymphocytes in peripheral airways of smokers wim chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-6.
97. Chung KF. The role of airway smooth muscle in the pathogenesis of airway wall remodeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:347-54. (Pubitemid 41699695)
98. Opazo Saez AM, Seow CY, Pare PD. Peripheral airway smooth muscle mechanics in obstructive airways disease. Am J Respir Crit Care Med 2000;161:910-7. (Pubitemid 30171751)
99. Baraldo S, Turato G, Badin C, Bazzan E, Beghé B, Zuin R et al. Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax 2004;59:308-12. (Pubitemid 38496748)
100. van Straaten JF, Coers W, Noordhoek JA, Huitema S, Flipsen JT, Kauffman HF et al. Proteoglycan changes in the extracellular matrix of lung tissue from patients with pulmonary emphysema. Mod Pathol 1999;12:697-705. (Pubitemid 29354883)
101. Neiwoehner DE, Kleinerman J, Rice DB. Pathologic changes in the airways of young cigarette smokers. N Engl J Med 1974;291:755-8.
102. Mitchell RS, Stanford RE, Johnson JM, Silvers GW, Dart G, George MS. The morphologic features of the bronchi, bronchioles and alveoli in chronic airway obstruction: A clinicopathological study. Am Rev Respir Dis 1976;114:137-45.
103. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J et al. The relations between structural changes in small airways and pulmonary function tests. N Engl J Med 1978;298:1277-81. (Pubitemid 8361451)
104. Wright JL, Lawson LM, Paré PD, Kennedy S, Wiggs B, Hogg JC. The detection of small airways disease. Am Rev Respir Dis 1984;129:989-94. (Pubitemid 14111759)
105. Mullen JBM, Wright JL, Wiggs BR, Paré PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br Med J (Clin Res Ed) 1985;291:1235-9. (Pubitemid 16223211)
106. Saetta M, Ghezzo H, Kim WD, King M, Angus GE, Wang NS et al. Loss of alveolar attachments in smokers: An early morpho-metric correlate of lung function impairment. Am Rev Respir Dis 1985;132:894-900. (Pubitemid 16247760)
107. Finkelstein R, Ma HD, Ghezzo H, Whittaker K, Fraser RS, Cosio MG. Morphometry of small airways in smokers and its relationship to emphysema type and hyperresponsiveness. Am J Respir Crit Care Med 1995;152:267-76.
108. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80. (Pubitemid 30490396)
109. Turato G, Zuin R, Miniati M, Baraldo S, Rea F, Beghé B et al. Airway inflammation in severe chronic obstructive pulmonary disease. Relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002;166:105-10. (Pubitemid 34693971)
110. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002;121(5 Suppl):160S-165S. (Pubitemid 34497335)
111. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009;360:2445-54.
112. Isajevs S, Taivans I, Strazda G, Kopeika U, Bukovskis M, Gordjusina V et al. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J 2009;33:61-7.
113. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-9. (Pubitemid 46828488)
114. Olloquequi J, Ferrer J, Montes JF, Rodríguez E, Montero MA, García-Valero J. Differential lymphocyte infiltration in small airways and lung parenchyma in COPD patients. Respir Med 2010a;104:1310-8.
115. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-59.
116. Richmond I, Pritchard GE, Ashcroft T, Avery A, Corris PA, Walters EH. Bronchus- associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non- smokers. Thorax 1993;48:1130-4. (Pubitemid 23336831)
117. Bonarius HP, Timens W, Brandsma CA, Roozendaal C, Koerts JA, Van de Berg A et al. Elevated anti-epithelial autoantibodies titer and increased cationic amino acids in IgH- CDR3 in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:A657.
118. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, Pilewski JM, Stoner MVV, Csizmadia E et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:156-63.
119. Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F et al. A Novel Insight into Adaptive Immunity in COPD: B Cell Activating Factor Belonging to the TNF Family (BAFF). Am J Respir Crit Care Med 2010 Jun 25. [Epub ahead of print].
120. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73. (Pubitemid 36583301)
121. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
122. Focosi D, Bestagno M, Burrone O, Petřini M. CD57+T lymphocytes and functional immune deficiency. J Leukoc Biol 2010;87:107-16.
123. Olloquequi J, Montes JF, Prats A, Rodriguez E, Montero MA, García-Valero J et al. Significant increase of CD57+ cells in pulmonary lymphoid follicles of COPD patients. Eur Respir J 2010b. [Epub ahead of print].
124. Barnes PJ. Macrophages as orchestrators of COPD. COPD 2004b; 1:59-70.
125. Pilette C, Colinet B, Kiss R, André S, Kaltner H, Gabius HJ et al. Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD. Eur Respir J 2007;29:914-22. (Pubitemid 46711895)
126. Tsoumakidou M, Koutsopoulos AV, Tzanakis N, Dambaki K, Tzortzaki E, Zakynthinos S et al. Decreased small airway and alveolar CD83+ dendritic ceils in COPD. Chest 2009;136:726-33.
127. Vassallo R, Walters PR, Lamont J, Kottom TJ, Yi ES, Limper AH. Cigarette smoke promotes dendritic cell accumulation in COPD; a lung tissue research consortium study. Respir Res 2010; 11:45-57.
128. Van Pottelberge GR, Bracke KR, Demedts IK, De Rijck K, Reinartz SM, van Drunen CM et al. Selective accumulation of langerhanstype dendritic cells in small airways of patients wim COPD. Respir Res 2010b 22;11:35.
129. Van Pottelberge GR, Bracke KR, Van den Broeck S, Reinartz SM, van Drunen CM, Wouters EF et al. Plasmacytoid dendritic cells in pulmonary lymphoid follicles of patients with COPD. Eur Respir J 2010a. [Epub ahead of print].
130. Demedts IK, Bracke KR, Van Pottelberge G, Testelmans D, Verleden GM, Vermassen FE et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:998-1005. (Pubitemid 46741751)
131. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004c;56:515-48. (Pubitemid 39658462)
132. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57-110. (Pubitemid 32566018)
133. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21. (Pubitemid 43209108)
134. Panina-Bordignon P, D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin PuIm Med 2003;9:104-10. (Pubitemid 36184560)
135. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000;190:619-26. (Pubitemid 30164493)
136. Tomaki M, Sugiura H, Koarai A, Komaki Y, Akita T, Matsumoto T et al. Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD. Pulmón Pharm Therap 2007;20:596-605. (Pubitemid 47077652)
137. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J et al. An immune basis for lung parenchymal destruction on chronic obstructive pulmonary disease and emphysema. PLOS Med 2004;1:75-83.
138. Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol 2007;171:767-76. (Pubitemid 47440976)
139. Saetta M, Mariáni M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1404-9. (Pubitemid 34522945)
140. Kelsen SG, Aksoy MO, Georgy M, Hershman R, Ji R, Li X et al. Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3. Am J Respir Crit Care Med 2009;179:799-805.
141. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, MaestrelIi P et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:894-901.
142. Rahman I, van Schadewijk AA, Crowther AJ, Hiemstra PS, Stolk J, MacNee W et al. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:490-5.
143. Brindicci C, Kharitonov SA, Ito M, Elliott MVV, Hogg JC, Barnes PJ et al. Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:21-30.
144. Maestrelli P, El Messlemani AH, De Fina O, Nowicki Y, Saetta M, Mapp C et al. Increased expression of heme oxygenase (HO)-I in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med 2001;164:1508-13. (Pubitemid 33124035)
145. Maestrelli P, Páska C, Saetta M, Turato G, Nowicki Y, Monti S et al. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 2003;21:971-6. (Pubitemid 36675612)
146. Puhakka AR, Harju TH, Pääkkö PK, Soini YM, Kinnula VL. Nitric oxide synthases are associated with bronchial dysplasia. Lung Cancer 2006;51:275-82. (Pubitemid 43265810)
147. Harju T, Kaarteenaho-Wiik R, Soini Y, Sormunen R, Kinnula VL. Diminished immunoreactivity of gamma-glutamylcysteine synthetase in the airways of smokers' lung. Am J Respir Crit Care Med 2002;166:754-9. (Pubitemid 34971862)
148. Rahman I, van Schadewijk AAM, Hiemstra PS, Stolk J, van Krieken JH, MacNee W et al. Localization of y-glutamylcysteine synthetase messenger RNA expression in lungs of smokers and patients with chronic obstructive pulmonary disease. Free Radie Biol Med 2000;28:920-5. (Pubitemid 30235165)
149. Harju TH, Peltoniemi MJ, Rytilä PH, Soini Y, Salmenkivi KM, Board PG et al. Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients. Respir Res 2007;8:48.
150. Harju T, MazurW, Merikallio H, Soini Y, Kinnula VL. Glutathiones- transferases in lung and sputum specimens, effects of smoking and COPD severity. Respir Res 2008;9:80.
151. Peltoniemi MJ, Rytilä PH, Harju TH, Soini YM, Salmenkivi KM, Ruddock LW et al. Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease. Respir Res 2006;7:133.
152. Harju T, Kaarteenaho-Wiik R, Sirvió R, Pääkkö P, Crapo JD, Oury TD et al. Manganese superoxide dismutase is increased in the airways of smokers' lungs. Eur Respir J 2004;24:765-71. (Pubitemid 39504429)
153. Suzuki M, Betsuyaku T, Ito Y, Nagai K, Nasuhara Y, Kaga K et al Down-regulated NF- E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2008b;39:673-82.
154. Malhotra D, Thimmulappa R, Vij N, Navas-Acien A, Sussan T, Merali S et al Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 2009;180:1196-207.
155. Aubert JD, Hayashi S, Hards J, Bai TR, Pare PD, Hogg JC. Plateletderived growth factor and its receptor in lungs from patients with asthma and chronic airflow obstruction. Am J Physiol 1994;266(6 Pt l):L655-63.
156. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M et al Increased expression of transforming growth factor-beta 1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001;163:1476-83. (Pubitemid 32506619)
157. Groneberg DA, Witt H, Adcock IM, Hansen G, Springer J. Smads as intracellular mediators of airway inflammation. Exp Lung Res 2004;30:223-50. (Pubitemid 38402445)
158. Zandvoort A, Postma DS, Jonker MR, Noordhoek JA, Vos JT, van der Geld YM et al. Altered expression of the Smad signalling pathway: implications for COPD pathogenesis. Eur Respir J 2006;28:533-41. (Pubitemid 44794667)
159. Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Saxena PR, Sterk PJ, de Boer WI et al. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-I. J Pathol 2005;206:28-38. (Pubitemid 40613431)
160. Kranenburg AR, De Boer WI, Van Krieken JH, Mooi WJ, Walters JE, Saxena PR et al. Enhanced expression of fibroblast growth factors and receptor FGFR-I during vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;27:517-25. (Pubitemid 35301805)
161. Baraldo S, Bazzan E, Zanin ME, Turato G, Garbisa S, Maestrelli P et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007;132:1733-40.
162. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000;117:684-94. (Pubitemid 30152206)
163. Yagi O, Aoshiba K, Nagai A. Activation of nuclear factor-KB in airway epithelial cells in patients with chronic obstructive pulmonary disease. Respiration 2006;73:610-6. (Pubitemid 44481477)
164. Adcock IM, Marwick J, Casolari P, Contoli M, Chung KF, Kirkham P, Papi A, Caramori G. Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD). Curr Pharm Des 2010;[Epub ahead of Mint].
165. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRTl, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:861-70. (Pubitemid 351600664)
166. Adcock IM, Chung KF, Caramori G, Ito K. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006;533:118-32. (Pubitemid 43340009)
167. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A et al Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-9.
168. Sturton G, Persson C, Barnes PJ. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sei 2008;29:340-5.
169. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D et al Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:6-14. (Pubitemid 43955238)
170. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008;32:472-86.
171. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ et al; American Thoracic Society and European Respiratory Society Task Force. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
172. Sin DD, Pahlavan PS, Man SF. Surfactant protein D: a lung specific biomarker in COPD? Ther Adv Respir Dis 2008;2:65-74. (Pubitemid 351472132)
173. Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol 2008;8:222-35.
174. Taylor DR, Pavord ID. Biomarkers in the assessment and management of airways diseases. Postgrad Med J 2008;84:628-34; quiz 633.
175. Bowman RV, Wright CM, Davidson MR, Francis SM, Yang IA, Fong KM. Epigenomic targets for the treatment of respiratory disease. Expert Opin Ther Targets 2009;13:625-40.